NYULMC CareSmarts Pilot

Status Completed

Clinical Trial Summary

CareSmarts is a theory-driven behavioral intervention designed to improve self-care among patients with Type 2 diabetes (T2D) with poor glycemic control (HbA1c>8%), through multiple mediators, including cuing, education, self-efficacy, social support, and health beliefs. Individuals will be randomly assigned with equal allocation to either the CareSmarts intervention or to usual care for 6 months.

Clinical Trial Description

CareSmarts is a mobile diabetes program that provides self-management support and team-based care management for people with diabetes through automated SMS messages. The program is a theory-driven behavioral intervention designed to improve self-care through multiple mediators, including cuing, education, self-efficacy, social support, and health beliefs. Participants in the program receive educational and motivational text messages about diabetes self-care, some prompts to engage in a particular action (for example, "Time to check your blood sugar"), and some self-assessment questions (such as, "Do you need refills of any of your medications?") to which the patient responds by texting. Participants' responses to self-assessment questions are used to facilitate remote monitoring and care management by the health care team. A response that is outside established parameters triggers an alert. Using protocols, nurses respond to each alert by the next business day. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02726217
Study type	Interventional
Source	New York University School of Medicine
Contact
Status	Completed
Phase	N/A
Start date	March 1, 2016
Completion date	May 2, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05594446` - Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
Completed	`NCT03975309` - DHS MIND Metabolomics
Completed	`NCT01855399` - Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes	N/A
Completed	`NCT01819129` - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes	Phase 3
Recruiting	`NCT04984226` - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD	Phase 2
Recruiting	`NCT05007990` - Caregiving Networks Across Disease Context and the Life Course
Active, not recruiting	`NCT04420936` - Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program	N/A
Recruiting	`NCT03549559` - Imaging Histone Deacetylase in the Heart	N/A
Completed	`NCT04903496` - Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
Completed	`NCT01437592` - Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects	Phase 1
Completed	`NCT01696266` - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed	`NCT04082585` - Total Health Improvement Program Research Project
Completed	`NCT03390179` - Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
Not yet recruiting	`NCT05029804` - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes	N/A
Recruiting	`NCT05294822` - Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes	N/A
Completed	`NCT04427982` - Dance and Diabetes/Prediabetes Self-Management	N/A
Completed	`NCT02356848` - STEP UP to Avert Amputation in Diabetes	N/A
Completed	`NCT03292185` - A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects	Phase 1
Active, not recruiting	`NCT05477368` - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes	N/A
Completed	`NCT04496401` - PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus	Phase 4